Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) ((MARAND-X))
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03163277|
Recruitment Status : Terminated (Sloww accrual and COVID-19 related problems (impossible to perform LPs))
First Posted : May 23, 2017
Last Update Posted : November 6, 2020
Neurocognitive disorders are still highly prevalent in the HAART era; despite a dramatic reduction in dementia cases, 15-50% of patients may develop mild or asymptomatic neurocognitive disorders (HIV-associated neurocognitive disorders, HAND).
Among other hypothesis neurotoxicity of antiretrovirals has been postulated but its impact is unknown.
Our hypothesis is that using drugs with reduced in vitro neurotoxicity may improve cognition in HIV-positive patients withHAND.
76 patients with HAND will be randomized to either continue their treatment or switch to emtricitabine, darunavir/cobicistat, maraviroc. Patients will be re-tested 6 months later.
|Condition or disease||Intervention/treatment||Phase|
|Hiv Neurocognitive Dysfunction||Drug: emtricitabine, darunavir/cobicistat, maraviroc||Phase 4|
Scientific Rationale for Study / Scientific Study Objectives:
Neurocognitive disorders are still highly prevalent in the HAART era; despite a dramatic reduction in dementia cases, 15-50% of patients may develop mild or asymptomatic neurocognitive disorders (HIV-associated neurocognitive disorders, HAND). It should be highlighted that patients presenting no abnormalities in everyday living activities (asymptomatic neurocognitive disorders, ANI) are at higher risk of worse results in performance-based tests, adherence-based measures and they show a significant risk of progressing to more severe forms of impairment. Excluding significantly confounding comorbidities, several factors have been associated with this neurocognitive decline including a low nadir CD4+ T-lymphocyte count, a high HIV DNA, a lower compartmental viral control, a lower concentration/penetration effectiveness score, a lower efficacy in macrophage-derived cells and antiretroviral-generated neuronal toxicity. However several data point out that vascular abnormalities, very common in HIV-positive patients, may deeply influence neurocognitive disorders development and severity: of note, intima media thickness, a well recognized proxy of systemic atherosclerosis, was associated with HAND.
In case of HAND diagnosis, the only recommended approach is to optimize treatment according to plasma and cerebrospinal fluid (CSF) resistance tests; no strategy is currently suggested in case of suppressed plasma and CSF HIV RNA or in case of low level CSF HIV RNA (without evidence of genotypic resistance). It has been postulated that antiretrovirals may have neurotoxic effects through different mechanisms and such effects might become evident once the beneficial effect of HIV RNA suppression vanishes. Available data suggest that, in vitro, the drugs associated with the least neurotoxic effect were emtricitabine, tenofovir, darunavir and maraviroc. Furthermore, several pieces of evidence and a small randomized trial suggest that maraviroc, in HAART-treated subjects may have beneficial effects in terms of improved neurocognitive function, reduced CSF inflammatory biomarkers and improved MRI markers of neuronal integrity.
No study has so far investigated the effect of using drugs with a low neurotoxic profile in HAART-treated patients with HAND.
Primary objective of the study is the variation in neurocognitive tests (global deficit score), 6 months after treatment switch while secondary objectives include the improvement in other biomarkers of neuronal and vascular integrity.
Study Design: Randomized, controlled, pilot study. HIV-positive patients that fulfill the inclusion criteria and that sign the informed consent will be enrolled. Patients will be randomized 1:1 (block randomization) to either continue their treatment or to switch to once-daily emtricitabine (200 mg) plus darunavir/cobicistat (800/150 mg) plus maraviroc (300 mg). A lumbar puncture will be performed 6 months after treatment switch.
Number of Patients: 76 (38 per arm)
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity|
|Actual Study Start Date :||May 15, 2017|
|Actual Primary Completion Date :||June 30, 2020|
|Actual Study Completion Date :||June 30, 2020|
No Intervention: Standard of care
Continue current antiretroviral regimen
Experimental: Reduced Neurotoxicity Arm
Emtricitabine plus darunavir/cobicistat plus maraviroc
Drug: emtricitabine, darunavir/cobicistat, maraviroc
- 6-month variation in global deficit score in NPZ-8 complete neurocognitive tests according to the study arm; [ Time Frame: 6 months ]Global deficit score
- rs-fMRI [ Time Frame: 6 months ]spectroscopic and perfusion markers at MRI as well as the variations in brain connectivity at resting state functional MRI;
- EEG-LORETA [ Time Frame: 6 months ]electroencephalographic waves using the LORETA software;
- CSF HIV RNA [ Time Frame: 6 months ]changes in CSF HIV RNA in the two arms
- CSF markers [ Time Frame: 6 months ]Variation in CSF markers of inflammation or neuronal damage
- Blood Brain Barrier Integrity [ Time Frame: 6 months ]Variation in CSAR in the two arms
- IMT [ Time Frame: 6 months ]Variation in carotid intima media thickness in the two arms
- TMAO [ Time Frame: 6 months ]Variation in trimethylamine-N-oxide in the two arms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03163277
|University of Torino|